ArticlePakistan journal of medical sciences2025
Clinical application of Azithromycin in treating pediatric Mycoplasma Pneumonia and its effects on platelet count, D-Dimer Levels, and Serum Inflammatory Factors.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical efficacy of azithromycin in treating pediatric mycoplasma pneumonia and its effects on platelet count, D-dimer levels, and serum inflammatory factors. Methodology: This was a retrospective study. Eighty children with mycoplasma pneumonia admitted to Anhui Children's Hospital between June 2022 to June 2024 were selected as study subjects. They were divided into an observation group(n=40) receiving azithromycin and a control group(n=40) receiving erythromycin according to different treatment strategies. Clinical efficacy, time to resolution of symptoms, platelet count, D-dimer levels, serum inflammatory factor levels, and incidence of adverse reactions were compared between the two groups. Results: The overall response rate of the observation group(95.00%) was significantly higher than that of the control group(72.50%)(χ Conclusion: Azithromycin offers multiple benefits in treating pediatric mycoplasma pneumonia, including rapid symptom resolution, potent anti-inflammatory effects, regulation of coagulation-fibrinolysis balance, reduction in serum inflammatory factor levels, and a lower incidence of adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.